Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1995 Jan;54(1):1–2. doi: 10.1136/ard.54.1.1

Osteoporosis in rheumatological practice: questions to be answered.

C Cooper 1
PMCID: PMC1005498  PMID: 7880114

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clinical indications for bone mass measurements. A report from the Scientific Advisory Board of the National Osteoporosis Foundation. J Bone Miner Res. 1989 Nov;4 (Suppl 2):1–28. doi: 10.1002/jbmr.5650040803. [DOI] [PubMed] [Google Scholar]
  2. Cooper C., Aihie A. Osteoporosis: recent advances in pathogenesis and treatment. Q J Med. 1994 Apr;87(4):203–209. [PubMed] [Google Scholar]
  3. Cummings S. R., Black D. M., Nevitt M. C., Browner W., Cauley J., Ensrud K., Genant H. K., Palermo L., Scott J., Vogt T. M. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993 Jan 9;341(8837):72–75. doi: 10.1016/0140-6736(93)92555-8. [DOI] [PubMed] [Google Scholar]
  4. Jergas M., Genant H. K. Current methods and recent advances in the diagnosis of osteoporosis. Arthritis Rheum. 1993 Dec;36(12):1649–1662. doi: 10.1002/art.1780361203. [DOI] [PubMed] [Google Scholar]
  5. Johnston C. C., Jr, Slemenda C. W., Melton L. J., 3rd Clinical use of bone densitometry. N Engl J Med. 1991 Apr 18;324(16):1105–1109. doi: 10.1056/NEJM199104183241606. [DOI] [PubMed] [Google Scholar]
  6. Law M. R., Wald N. J., Meade T. W. Strategies for prevention of osteoporosis and hip fracture. BMJ. 1991 Aug 24;303(6800):453–459. doi: 10.1136/bmj.303.6800.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lukert B. P., Johnson B. E., Robinson R. G. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res. 1992 Sep;7(9):1063–1069. doi: 10.1002/jbmr.5650070909. [DOI] [PubMed] [Google Scholar]
  8. Melton L. J., 3rd, Atkinson E. J., O'Fallon W. M., Wahner H. W., Riggs B. L. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993 Oct;8(10):1227–1233. doi: 10.1002/jbmr.5650081010. [DOI] [PubMed] [Google Scholar]
  9. Mulder H., Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol. 1994 Apr;33(4):348–350. doi: 10.1093/rheumatology/33.4.348. [DOI] [PubMed] [Google Scholar]
  10. Peat I. D., Healy S., Reid D. M., Ralston S. H. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis. 1995 Jan;54(1):66–68. doi: 10.1136/ard.54.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Peel N., Eastell R. Measurement of bone mass and turnover. Baillieres Clin Rheumatol. 1993 Oct;7(3):479–498. doi: 10.1016/s0950-3579(05)80074-3. [DOI] [PubMed] [Google Scholar]
  12. Reid I. R., King A. R., Alexander C. J., Ibbertson H. K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988 Jan 23;1(8578):143–146. doi: 10.1016/s0140-6736(88)92721-3. [DOI] [PubMed] [Google Scholar]
  13. Sambrook P., Birmingham J., Kelly P., Kempler S., Nguyen T., Pocock N., Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993 Jun 17;328(24):1747–1752. doi: 10.1056/NEJM199306173282404. [DOI] [PubMed] [Google Scholar]
  14. Spector T. D., Sambrook P. N. Steroid osteoporosis. BMJ. 1993 Aug 28;307(6903):519–520. doi: 10.1136/bmj.307.6903.519. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES